Additionally, PMS2-negative status was more frequently observed in signet-ring cell adenocarcinomas (20%) and mucinous adenocarcinomas (16.1%) compared to NOS adenocarcinomas (12.5%) or neuroendocrine tumors (0%), though these differences were not statistically significant (p = 0.531). This evidence concerns the gene PMS2 and neuroendocrine neoplasm.